Loading people...
Julia Kaufman is an Investment Manager at the Boehringer Ingelheim Venture Fund based in Cambridge, Massachusetts. She holds a PhD in Immunology from the University of Rochester School of Medicine and Dentistry and previously conducted molecular neuro-oncology research at Rockefeller University starting in 2002. Kaufman joined Boehringer Ingelheim Pharmaceuticals in 2014, where she served as a Laboratory Head, Disease Positioning Lead, and Research Project Leader leading Phase 1 clinical studies in immunology and respiratory diseases before transitioning to the venture fund in 2022. In her current investing capacity, she serves as a board representative for Rgenta Therapeutics following a 2019 investment and has participated in financing rounds for biotechnology startups such as STRM.BIO. Her primary professional focus remains on early-stage therapeutics investments and new company formation across the oncology, neurology, and immunology sectors.
Julia Kaufman serves as a dedicated Investor at the Boehringer Ingelheim Venture Fund (BIVF), a corporate venture capital arm committed to identifying and nurturing innovative early stage companies in the life sciences. In her pivotal role, Julia is instrumental in sourcing, evaluating, and executing investments in biotech, pharmaceutical, and digital health startups that promise to revolutionize patient care. Her work directly supports BIVF's mission to invest in groundbreaking science and technology that complements Boehringer Ingelheim's strategic therapeutic areas.
Julia Kaufman's investment focus is broad yet targeted, encompassing novel therapeutic platforms, cutting edge drug discovery technologies, and transformative digital health solutions. She actively seeks out companies developing first in class or best in class therapies across areas such as cardiovascular diseases, central nervous system disorders, immunology, oncology, and respiratory conditions. Furthermore, Julia has a keen interest in disruptive technologies that enhance drug development processes, improve patient outcomes, or enable precision medicine. Her analytical approach ensures that potential portfolio companies not only possess robust scientific foundations but also strong commercial viability and strategic alignment with BIVF's long term vision.
Prior to joining the Boehringer Ingelheim Venture Fund, Julia Kaufman built a distinguished career spanning scientific research, business development, and venture capital. Her background often includes advanced degrees in life sciences, providing her with a deep understanding of complex biological mechanisms and drug development pathways. This scientific rigor, combined with extensive experience in evaluating market opportunities and strategic partnerships, makes her an invaluable asset to the BIVF team. She has a proven track record of identifying promising early stage ventures and guiding them through critical growth phases, leveraging her network and expertise to accelerate their progress.
While specific investment names are proprietary or not publicly detailed for every investor, Julia Kaufman's contributions are evident in the strategic growth of BIVF's portfolio. She is known for her hands on approach, working closely with founders and management teams to navigate scientific, clinical, and operational challenges. Her investments aim to bring forward therapies and solutions that address significant unmet medical needs, ultimately contributing to Boehringer Ingelheim's commitment to improving human and animal health. Julia's strategic insights help shape companies from preclinical stages through to clinical development, positioning them for success in a competitive landscape.
Julia Kaufman embodies the innovative spirit of the Boehringer Ingelheim Venture Fund, driving investments that have the potential to redefine healthcare. Her dedication to fostering scientific breakthroughs and supporting visionary entrepreneurs makes her a respected figure in the sciences investment community.
Julia Kaufman is an investor at the Boehringer Ingelheim Venture Fund, specializing in early stage biotech, pharmaceutical, and digital health investments. She identifies and supports innovative companies aiming to transform patient care.
Julia Kaufman invests in novel therapeutic platforms, cutting edge drug discovery technologies, and transformative digital health solutions. Her focus areas align with Boehringer Ingelheim's strategic interests, including cardiovascular, CNS, immunology, oncology, and respiratory conditions.
Julia Kaufman works as an Investor at the Boehringer Ingelheim Venture Fund, the corporate venture capital arm of Boehringer Ingelheim.
